Research Grade FoundationChemical Characteristics:Combination of regenerative peptides
), taurine, L-Carnitine, basic white emulsion (E 1450, E 445, E 300, E 307), preservatives (potassium sorbate, sodium benzoate), sweeteners (acesulfame K, sucralose), caffeine
Most notably, the FLOW trial, the first dedicated GLP-1 RA kidney outcome trial, demonstrated that once-weekly semaglutide reduced the risk of sustained decline in estimated glomerular filtration rate (eGFR), kidney failure or cardiovascular death in people with CKD and T2D [9]
The most common effects are mild nausea, upset stomach, bloating, and changes in bowel habits, especially when starting or raising the dose